UY30973A1 - Metodo para tratar el dolor mediado por los receptores de cb2 (i) - Google Patents

Metodo para tratar el dolor mediado por los receptores de cb2 (i)

Info

Publication number
UY30973A1
UY30973A1 UY30973A UY30973A UY30973A1 UY 30973 A1 UY30973 A1 UY 30973A1 UY 30973 A UY30973 A UY 30973A UY 30973 A UY30973 A UY 30973A UY 30973 A1 UY30973 A1 UY 30973A1
Authority
UY
Uruguay
Prior art keywords
receivers
treat pain
pain mediated
subject
mediated
Prior art date
Application number
UY30973A
Other languages
English (en)
Spanish (es)
Inventor
Mingde Xia
Kevin Paul Pavlick
Mark J Macielag
Christopher Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30973(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY30973A1 publication Critical patent/UY30973A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY30973A 2007-03-21 2008-03-19 Metodo para tratar el dolor mediado por los receptores de cb2 (i) UY30973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89601407P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
UY30973A1 true UY30973A1 (es) 2008-09-30

Family

ID=39766329

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30973A UY30973A1 (es) 2007-03-21 2008-03-19 Metodo para tratar el dolor mediado por los receptores de cb2 (i)

Country Status (14)

Country Link
US (1) US20080234347A1 (enExample)
EP (1) EP2139326A4 (enExample)
JP (1) JP2010522181A (enExample)
KR (1) KR20090120499A (enExample)
CN (1) CN101677556A (enExample)
AR (1) AR065800A1 (enExample)
AU (1) AU2008229264A1 (enExample)
CA (1) CA2681381A1 (enExample)
CL (1) CL2008000827A1 (enExample)
MX (1) MX2009010162A (enExample)
PE (1) PE20090062A1 (enExample)
TW (1) TW200901972A (enExample)
UY (1) UY30973A1 (enExample)
WO (1) WO2008115671A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282147B (zh) * 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 二环吡唑并-杂环
KR20200088765A (ko) * 2017-11-15 2020-07-23 파낙 파마 인코퍼레이티드 간질성 방광염의 치료 방법
CN122555695A (zh) 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
US7452997B2 (en) * 2004-03-24 2008-11-18 Janssen Pharmaceutica, N.V. Tetrahydro-indazole cannabinoid modulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
ES2375213T3 (es) * 2005-09-23 2012-02-27 Janssen Pharmaceutica Nv Moduladores de cannabinoides de hexadhidro-cicloheptapirazol.
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators

Also Published As

Publication number Publication date
AR065800A1 (es) 2009-07-01
CL2008000827A1 (es) 2008-09-26
KR20090120499A (ko) 2009-11-24
JP2010522181A (ja) 2010-07-01
CA2681381A1 (en) 2008-09-25
MX2009010162A (es) 2009-10-12
TW200901972A (en) 2009-01-16
AU2008229264A1 (en) 2008-09-25
WO2008115671A1 (en) 2008-09-25
EP2139326A1 (en) 2010-01-06
PE20090062A1 (es) 2009-01-26
US20080234347A1 (en) 2008-09-25
EP2139326A4 (en) 2011-06-15
CN101677556A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
CO6341577A2 (es) Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos
PA8841901A1 (es) Compuestos orgánicos
CL2019003798A1 (es) Métodos para tratar la enfermedad de huntington.
UY32110A (es) Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad
UY32111A (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CU20110142A6 (es) Procedimiento para tratar enfermedades inflamatorias o alérgicas
CO6341558A2 (es) Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos
EA201290919A1 (ru) Индазольные соединения и их применение
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
ECSP12011815A (es) Métodos sintéticos para compuestos espiro-oxoindol
MX347902B (es) Composicion para el alivio del dolor, que comprende un agonista selectivo de trpv1, y manufactura y usos de la misma.
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
ECSP10010518A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ECSP14016162A (es) Combinaciones de compuestos activos
CR20130490A (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y métodos de tratamiento de las mismas
MX353096B (es) Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
PA8850801A1 (es) Compuestos útiles para inhibir chk1
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX339050B (es) Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
UA107562C2 (uk) Спосіб лікування псоріазу
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos